Literature DB >> 22271720

The ulcerated leg: when to revascularize.

J A P Apelqvist1, M J A Lepäntalo.   

Abstract

The role of peripheral arterial disease in ulcerated diabetic feet has long been underestimated. Progressive claudication, rest pain and the extent of irreversible tissue loss have frequently been indications for revascularization for neuroischaemic ulcers in diabetic patients. These typical ischaemic symptoms are warning signs that are less frequent in diabetic individuals with ischaemia than those without diabetes. Consequently, 30-50% of individuals with diabetes and foot ulcers already have gangrene at admission and are therefore often considered unsuitable for revascularization. Furthermore, the healing of a neuroischaemic ulcer is worsened by microvascular dysfunction, causing arteriovenous shunting, capillary ischaemia, leakage and venous pooling. Therefore, the threshold of revascularizing neuroischaemic ulcers should be lower than that of purely ischaemic ulcers. Comorbidity, ulcer characteristics and infection affect the decision as to when to intervene, as do the severity and extent of occlusive arterial lesions. The window of opportunity for vascular intervention in the neuroischaemic diabetic foot should not be missed, and the need for early vascular intervention as an integrated part of a strategy to achieve healing should be emphasized. Noninvasive vascular testing should be performed on all individuals with an ulcerated diabetic foot. The arterial tree should be imaged if noninvasive tests indicate ischaemia or when mild or questionable ischaemia is diagnosed and conservative treatment does not promote ulcer healing in 6 weeks. Revascularization should be performed whenever feasible to repair distal perfusion to achieve ulcer healing.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22271720     DOI: 10.1002/dmrr.2259

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  4 in total

1.  PKCβ increases ROS levels leading to vascular endothelial injury in diabetic foot ulcers.

Authors:  Zhichuan Liu; Ling Hu; Tao Zhang; Hang Xu; Hailin Li; Zhouqian Yang; Mei Zhou; Hendrea Shaniqua Smith; Jing Li; Jianhua Ran; Zhongliang Deng
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs.

Authors:  Raffaele Serra; Luca Gallelli; Angela Conti; Giovanni De Caridi; Mafalda Massara; Francesco Spinelli; Gianluca Buffone; Francesco Giuseppe Caliò; Bruno Amato; Simona Ceglia; Giuseppe Spaziano; Luca Scaramuzzino; Alessia Giovanna Ferrarese; Raffaele Grande; Stefano de Franciscis
Journal:  Drug Des Devel Ther       Date:  2014-05-13       Impact factor: 4.162

3.  Management of peripheral arterial disease in diabetes: a national survey of podiatry practice in the United Kingdom.

Authors:  Pasha Normahani; Chira Mustafa; Nigel J Standfield; Claire Duguid; Martin Fox; Usman Jaffer
Journal:  J Foot Ankle Res       Date:  2018-06-08       Impact factor: 2.303

4.  Current concepts for the evaluation and management of diabetic foot ulcers.

Authors:  Andreas F Mavrogenis; Panayiotis D Megaloikonomos; Thekla Antoniadou; Vasilios G Igoumenou; Georgios N Panagopoulos; Leonidas Dimopoulos; Konstantinos G Moulakakis; George S Sfyroeras; Andreas Lazaris
Journal:  EFORT Open Rev       Date:  2018-09-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.